News and reporting on prostate cancer.
Total revenue for the quarter was $85.5 million compared to $82 million in Q2 2016, while net loss shrank to $2.7 million or $.08 per share.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.
Bioinformatics firm Berg is combining multi-omics data from the Department of Defense's Center for Prostate Disease Research in search of biomarkers.
The company's validation studies demonstrate that the assay has a 99 percent negative predictive value, which it believes will persuade physicians of its value.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
The company has contracted IPS Genomix to distribute the SelectMDx test in Lebanon, Egypt, the UAE, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan.
A small study of prostate cancers from African American and European American men uncovered ancestry-associated splicing with apparent ties to tumor aggressiveness and resistance.
The tests were previously available in New York state on a patient-by-patient basis through a non-permitted laboratory testing program.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.
LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.
The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.
In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.